Angiotensin receptor blockers and myocardial infarction

BMJ 2005; 330 doi: https://doi.org/10.1136/bmj.330.7502.1269-a (Published 26 May 2005) Cite this as: BMJ 2005;330:1269

Results reflect different cardiovascular states in patients with types 1 and 2 diabetes

  1. Edmund J Lewis, principal investigator, Collaborative Study Group (Helen_Follmer@rush.edu)1,
  2. Collaborative Study Group
  1. 1Section of Nephrology, Rush University Medical Center, 1653 W Congress Parkway, Chicago, IL 60612, USA

    Editor—Verma and Strauss's editorial supports the contention that angiotensin receptor blockers are associated with increased risk of myocardial infarction.1 Included in the documentation of this risk are briefing documents from the US Food and Drug Administration quoting data from the irbesartan diabetic nephropathy trial.2 However, the authors did not cite our published analysis of cardiovascular events during this trial.3 Omitted was any mention that the difference …

    View Full Text

    Log in

    Log in through your institution


    * For online subscription